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Abstract
Background: Circulating vascular adhesion molecule-1 (sVCAM-1) is a presumed marker of endothelial activation
and dysfunction, but little is known about its association with mood. We hypothesized that elevated plasma
concentrations of sVCAM-1 may be a marker of depressive symptoms due to cerebral vascular disease.
Methods: We studied 680 community-dwelling participants in the MOBILIZE Boston Study, aged 65 years and
older. sICAM-1 and sVCAM-1 were measured by ELISA assay and depressive symptoms were assessed during
home interviews using the Revised Center for Epidemiological Studies Depression Scale (CESD-R). Cerebral
White Matter Hyperintensities (WMHs) were quantified by MRI in a subgroup of 25 participants.
Results: One hundred seventy nine (27 %) subjects had a CESD-R Score≥ 16, indicative of depressive symptoms. The
mean sVCAM-1 concentration (±SD) was 1176 ± 417 ng/mL in a group with CESD-R Scores <16 and 1239 ± 451 ng/mL
in those with CESD-R Scores ≥16 (p = 0.036). CESD-R Score was positively associated with sVCAM-1 (r = 0.11, p = 0.004).
The highest quintile of sVCAM-1, which is indicative of endothelial dysfunction, was significantly associated with
depressive symptoms compared to the lowest quintile (OR = 1.97 (1.14-3.57) p = 0.015). In a subset of subjects,
sVCAM-1 concentration was positively correlated with cerebral WMHs volume (p = 0.018).
Conclusions: The association between high levels of sVCAM-1 and depressive symptoms may be due to endothelial
dysfunction from cerebral microvascular damage. Future longitudinal studies are needed to determine whether
sVCAM-1 can serve as a biomarker for cerebrovascular causes of depression.
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Backgound
Aging is associated with depressive symptoms, which are
an important risk factor for cardiovascular morbidity
and mortality [1]. National data from households of
adults in the United States show that two-thirds of all
those aged 50 years and older who had depression symp-
toms had a diagnosis of heart disease, stroke, hyperten-
sion, and/or diabetes [2]. Depressive symptoms have
been also associated with a higher risk of cardiovascular
death [3, 4]; and decreased quality of life [5].
Circulating Vascular Cell Adhesion molecule-1 (sVCAM-1)
and Intercellular Adhesion Molecule-1 (sICAM-1) are well-
known biomarkers of endothelial activation and dys-
function and are associated with an increased risk of
hypertension and atherosclerosis [6, 7]. In human studies,
increased concentrations of circulating soluble adhesion
molecules (CAMs) have been reported in patients with sys-
temic inflammatory and cardiovascular diseases [8, 9].
Increased levels of soluble CAMs in patients with hyperlip-
idemia may be a marker for atherosclerosis [10]. Increased
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concentrations of CAMs have also been associated with
multiple organ dysfunction, disease severity, or death [11].
It has been hypothesized that late-life depression may be
due in part to cerebrovascular disease [12, 13]. Ischemia
has been shown to induce the expression of ICAM-1 [14].
In post-mortem studies there is an increased expression of
CAMs in the dorsolateral prefrontal cortex in people with
depressive symptoms [15], which is consistent with a the-
ory of vascular depression [16, 17]. In addition, there is a
correlation between sICAM-1 and depressive symptoms
during treatment of melanoma with interferon [18].
We hypothesized that elevated plasma concentrations of
circulating CAMs associated with aging may be a marker
of depressive symptoms due to cerebral vascular disease.
We therefore used plasma biomarkers and data from the
MOBILIZE Boston Study (Maintenance Of Balance,
Independent Living, Intellect, and Zest in the Elderly)
to explore the relationships between plasma levels of
CAMs and depressive symptoms in a community-
based population of older adults.
Materials and Methods
Participants
The study sample consisted of 680 community-dwelling
seniors living in the Boston area who participated in the
MOBILIZE Boston Study (MBS). The design and method-
ology for this study have been previously described in de-
tail [19, 20]. In brief, 765 persons were enrolled using
door-to-door population based recruitment. To be in-
cluded, individuals had to be > 65 years, able to under-
stand and communicate in English, able to walk 20 feet
without personal assistance (walking aids permitted), and
expected to live in the area for at least 2 years. Exclusion
criteria included terminal disease, severe vision or hearing
deficits, and Mini-Mental State Examination score <18
[21, 22]. All subjects underwent a complete home and la-
boratory assessment of demographic characteristics, med-
ical conditions, medications, functional status, gait speed,
smoking status, alcohol use, blood pressure, and cerebral
hemodynamics at baseline.
Depressive Symptoms Assessment
Depressive symptoms were assessed at study enrollment
using the Revised Center for Epidemiologic Studies
Depression scale (CESD-R) [23]. The CESD-R is a 20-item
self-administered instrument designed to measure the
presence of depressive symptoms over the previous two
weeks in community studies. Note that the CESD-R does
not capture information on a patient's clinical or treat-
ment history and is not useful as a diagnostic tool for de-
pression. The CESD-R has been validated [24, 25]. As in
previous work [26], we chose a priori to use scores of <16
to indicate no or minimal depressive symptoms and ≥16
to indicate the presence of moderate or severe symptoms.
Biomarker measures
Plasma concentrations of sICAM-1, sVCAM-1, and
interleukin-6 (IL-6) were measured by ELISA assay (R&D
Systems, Minneapolis, MN). For sICAM-1 this assay has a
sensitivity of 0.35 ng/mL, and the day-to-day variability of
the assay at concentrations of 64.2, 117, 290 and 453 ng/
mL are 10.1, 7.4, 6.0 and 6.1 %, respectively. For sVCAM-
1 the assay has a sensitivity of 2.0 ng/mL and the day-to-
day variability of the assay at concentrations of 9.8, 24.9
and 49.6 ng/mL is 10.2, 8.5 and 8.9 %, respectively. For
IL-6, the assay has a sensitivity of 0.094 pg/mL, and the
day-to-day variability of the assay at concentrations of
0.49, 2.78 and 5.65 pg/mL are 9.6, 7.2 and 6.5 %, respect-
ively. In addition, the concentration of high sensitivity
C-reactive protein (hsCRP) was determined using an
immunoturbidimetric assay on a Hitachi 917 analyzer
(Roche Diagnostics - Indianapolis, IN), using reagents
and calibrators from DiaSorin (Stillwater, MN). This high-
sensitivity assay has a limit of detection of 0.03 mg/L. The
day-to-day variability of the assay at concentrations of
0.91, 3.07 and 13.38 mg/L are 2.81, 1.61 and 1.1 %, re-
spectively. All assays were performed by Dr. Nader Rifai’s
group at Boston Children’s Hospital.
Magnetic Resonance Image data
Volumes of cerebral white matter hyperintensities (WMH)
normalized by intracranial volume were estimated from the
MRI data in a subset of 25 MBS participants who com-
pleted MRI substudy. Eligible and willing participants were
imaged using a Siemens Trio 3 Tesla system (Erlangen,
Germany) employing a 12-channel phased-array head
coil for reception and body coil for transmission. Cerebral
WMH were measured with Free Surfer (http://surfer.
nmr.mgh.harvard.edu) using a multispectral procedure
that classifies white matter as normal or abnormal from
signal intensities from the T1, PD, and T2 images at each
voxel. The Free Surfer procedure for lesion segmentation
combines the initial standard segmentation with an ex-
tension of the subcortical segmentation procedure that
incorporates information from a co registered T2 and
PD image for the segmentation of signal abnormalities
within the white matter. Although the procedure with
T1-weighted images alone tends to underestimate white
matter lesion volumes, the incorporation of information
from T2/PD provides more robust estimation of the le-
sion volumes. The multiple image modalities were regis-
tered to the T1 with boundary-based registration (BBR)
and the segmentation of WMH from healthy WM was
accomplished with a multispectral Gaussian classifier
for each subject based on the atlas values.
Other covariates
Covariates included sociodemographic characteristics, health
status, and amount of physical activity. Sociodemographic
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characteristics assessed in the home interview included age,
sex, race (self-identified), and years of education. We used
the validated Physical Activity Scale for the Elderly (PASE)
to measure physical activity in the previous week [27].
Participants were asked about physician-diagnosed
major medical conditions. Details of the study variables
have been published previously [19, 20]. Diabetes was
defined using an algorithm based on self-reported dia-
betes, use of antidiabetic medications, and laboratory
measures from the baseline clinic visit, including ran-
dom glucose (≥200 mg/dL) and hemoglobin A1c (≥7 %).
Body mass index (calculated as weight in kilograms di-
vided by height in meters squared) was calculated from
measured height and weight. Comorbidity index was the
number of comorbidities or medical conditions. Medica-
tion use (antihypertensive, antidepressant, and benzodi-
azepine) was also assessed.
Ethics Statement
The MOBILIZE Boston Study was reviewed and ap-
proved by the Hebrew SeniorLife Institutional Review
Board (IRB). Written informed consent was obtained
from each participant. The study was conducted accord-
ing to the principles of the Helsinki Declaration.
Data Analysis
Concentrations of sVCAM-1 and sICAM-1 were natural
log-transformed to approximate a normal distribution
prior to modeling as continuous variables. We also di-
vided the distributions of sVCAM-1 and sICAM-1 into
quintiles according to the distribution in the entire study
population for categorical analyses. We compared base-
line characteristics of different groups of study partici-
pants by using t tests, χ2 tests, or Wilcoxon rank-sum
tests, as appropriate.
We used multivariate logistic regression to estimate the
odds ratio and 95 % confidence intervals (CIs) for quintiles
of sVCAM-1 and sICAM-1 and depressive symptoms
Table 1 Characteristics of participants according to CESD-R
score status (<16 vs. ≥ 16), N = 668*
Baseline Characteristics CESD-R scorea P Value‡
<16
(n = 489, 73 %)
≥16
(n = 179, 26 %)
Demographics
Age, mean (SD), y 77.9 ± 5.3 78.4 ± 5.5 0.44
Gender 0.071
Men 193 (39.5) 57 (31.8)
Women 296 (60.5) 122 (68.2)
White Race 397 (81.2) 138 (77.0) 0.58
Educational level,
mean (SD), y
14.98 ± 5.1 14.97 ± 8.1 0.11
Health behaviors
Body mass index, kg/m2,b 0.31
<25 148 (30.3) 62 (34.6)
25-29.9 208 (42.5) 78 (43.6)
≥30 133 (27.2) 39 (21.8)
Current smoker 283 (57.9) 102 (57.) 0.84
Alcohol use (Endorsing ≥2
drinks per week)
136 (27.8) 35 (19.6) 0.03
Physical activity scorec 0.024
0- 66 139 (28.4) 68 (38.0)
66.01-124 164 (33.5) 59 (33.0)
124.01-559 181 (37.0) 49 (27.4)
Health conditions
Comorbidity index 2.8 ± 1.4 3.8 ± 1.8 <.0001
Hypertension 374 (76.5) 147 (82.1) 0.075
Hyperlipidemia 285 (58.3) 103 (57.5) 0.54
Diabetes 84 (17.2 42 (23.5) 0.066
Previous Stroke 39 (8.0) 27 (15.1) 0.007
Coronary artery disease 67 (13.7) 40 (22.4) 0.0044
Congestive Heart failure 16 (3.3) 18 (10.1) 0.0004
Cognitive impairment
(MMSE < 24)d




320 (65.4) 134 (74.86) 0.024




3.8 ± 12.3 5.3 ± 14.8 0.19
Interleukin-6, mean (SD),
pg/mL
3.8 ± 7.5 4.2 ± 5.7 0.046
Table 1 Characteristics of participants according to CESD-R
score status (<16 vs. ≥ 16), N = 668* (Continued)
Soluble ICAM-1, mean (SD),
ng/mL
258 ± 75 273 ± 87 0.064
Soluble VCAM-1, mean (SD),
ng/mL
1176 ± 417 1239 ± 451 0.036
sVCAM-1 Soluble Vascular Cell Adhesion Molecule-1, sICAM-1 Soluble Inter
Cellular Adhesion Molecule-1. *Missing values = 12 from 680;‡Global test:
χ2 or Fisher’s exact test for binary variables; analysis of variance for
continuous variables.
aCESD-R, Center for Epidemiological Studies Depression Scale Revised
bBody mass index is calculated as weight in kilograms divided by height in
meters squared
cPhysical activity tertiles measured using the Physical Activity Scale for
the Elderly
dMini-Mental State Examination (MMSE) cut off point for cognitive impairment
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(CESD-R Score ≥16). Analyses were adjust for the following
groups of confounders: 1) other biomarkers (IL6, C-
Reactive Protein); 2) socio-demographic conditions (age,
gender, white race, education level, BMI, current smoker,
alcohol use); 3) Health conditions (diabetes, hypertension,
congestive heart failure, hyperlipidemia, cognitive status,
any cardiovascular medications, coronary disease, previous
stroke), and 4) physical activity level.
Subjects with missing data for depressive symptoms,
sVCAM-1 and sICAM-1 were excluded. All analyses
were performed using SAS software, version 9.3 (SAS
Institute Inc, Cary, North Carolina). A two-sided P value




As shown in Table 1, 489 (73.2 %) participants had no
depression symptoms and 179 (26.8 %) had depressive
symptoms. The mean IL6 was significantly higher in
those with depression symptoms. 605 (90.6 %) had a
least one cardiovascular disease, those with depression
had significantly more co-morbidities (p < 0.0001) and
performed less physical activity (p = 0.007) than those
without.
Although IL6 was higher in the group with depressive
symptoms, it was not linearly correlated with CESD-R
score (r = 0.03 p = 0.32).
2. Soluble VCAM-1 and Depression symptoms (CESD-R ≥16)
The mean sVCAM-1 concentration was 1177. ± 417 in
the group without depressive symptoms (CESD-R < 16)
and 1239 ± 451 in the group with depressive symptoms
(CESD-R ≥ 16) (p = 0.036). Univariate logistic regression
analyses showed associations between sVCAM-1 and
many cardiovascular diseases, comorbidity index, and
less physical activity (Table 2). The unadjusted model
(Model 1) showed that the highest quintile of sVCAM-1
was associated with depression symptoms (CESD-R ≥16)
(OR = 2.28 (1.24 – 3.84) p = 0.0066). After adjustment,
the final multivariate logistic regression model (Model 4)
showed that the highest quintile of sVCAM-1 compared
to lowest quintile was significantly associated with de-
pressive symptoms (CESD-R ≥16) (OR = 1.97 (1.14 – 3.57)
p = 0.015) (Table 3).
3. Soluble ICAM-1 and other biomarkers
sICAM-1 and hs-CRP concentrations were both weakly
correlated with CESD-R score (respectively, r = 0.12 p =
0.0028 and r = 0.08 p = 0.046. After adjustment for
sVCAM-1, age, gender, white race health condition and
physical activity score, the final model showed no signifi-
cant relationships between depressive symptoms and
these biomarkers.
4. Cerebral WMHs, sVCAM-1, and Depression symptoms
Table 4 summarizes the characteristics of the 25 partici-
pants with brain MRI data.
We observed that cerebral WMH volume was corre-
lated with sVCAM-1 concentration (r = 0.47 p = 0.018)
and the association still significant when adjusted for co-
morbidity index (Fig 1).
WMHs volumes were also higher among participants
with CESD-R ≥ 16; 22.43 mL vs. 10.78 mL (p = 0.039)
Table 2 Univariate logistic regression model with CESD-R score
status ( <16 vs. ≥ 16)a, N = 668*
Baseline Characteristics OR 95%CI P Value
Age, mean (SD), y 1.1 (0.99, 1.05) 0.30
Gender
Men 1.0 Reference
Women 1.4 (0.97, 2.01) 0.072
Race
Other race 1.0 Reference
White Race 0.8 (0.49, 1.28) 0.34
Body mass index, kg/m2,b
<25 1.18 (0.75, 1.66) 0.58
25-29.9 1.00 Reference
≥30 0.78 (0.50, 1.22) 0.27
Current smoker 0.96 (0.68, 1.36) 0.84
Alcohol use (Endorsing ≥2 drinks per week) 0.63 (0.42, 0.96) 0.031
Physical activity scorec
0- 66 1.81 (1.18, 2.77) 0.007
66.01-124 1.33 (0.86, 2.05) 0.20
124.01-559 1.00 Reference
Comorbidity index 1.49 (1.32, 167) <.0001
Hypertension 1.50 (0.96, 2.36) 0.076
Hyperlipidemia 1.06 (0.74, 1.54) 0.74
Diabetes 1.48 (0.97, 2.25) 0.067
Previous Stroke 2.05 (1.21, 3.45) 0.0075
Cognitive impairment (MMSE < 24)d 2.14 (1.30, 3.55) 0.003
Congestive Heart failure 3.33 (1.66, 6.67) 0.0007
Coronary artery disease 1.23 (1.07, 1.43) 0.0048
Any cardiovascular medication 1.56 (1.06, 2.30) 0.025
Psychotropic Medication 1.50 (0.79, 2.81) 0.21
*Missing values = 12 from 680.
aCESD-R, Center for Epidemiological Studies Depression Scale Revised
bBody mass index is calculated as weight in kilograms divided by height in
meters squared
cPhysical activity tertiles measured using the Physical Activity Scale for
the Elderly
dMini-Mental State Examination (MMSE) cut off point for cognitive impairment
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but not reach statistical significance when adjusted for
comorbidity index (p = 0.056).
Discussion
The results of this study showed cross-sectional associa-
tions between elevated plasma levels of sVCAM-1 and 1)
depressive symptoms, and 2) cerebral white matter dam-
age among older community-dwelling adults.
Research suggests that mood can become impaired when
one or more of the brain’s frontal-subcortical circuits are
damaged [28, 29]. Three of these circuits (dorsolateral pre-
frontal, lateral orbitofrontal, and medial frontal/anterior
cingulate) play an important role in mood regulation, and
damage in these areas produces a neurobehavioral syn-
drome. Previous studies suggested that a relationships be-
tween white matter hyperintensities, cerebral blood flow
regulations [30, 31]. Brain endothelial dysfunction indicated
by higher levels of sVCAM-1 may be a key pathogenic
mechanism. Elevated levels of plasma sVCAM-1 concentra-
tion (>1200 ng/mL) may signal vascular damage in the
cerebral white matter that carries axons from frontal-
subcortical circuits involved in mood regulation. Further-
more, endothelial dysfunction may impair cerebral blood
flow regulation, resulting in ischemic damage to these cir-
cuits [32, 33].
Previous work by our group and others [34] has shown
that elevations in sVCAM-1 are associated with abnormal
CO2 vasoreactivity in the brain. Those with depressive
Table 3 Odds ratio from logistic regression relationship between levels of soluble VCAM-1 and depression symptoms (CESD-R
score ≥16), No. = 668†
Quintiles of sVCAM-1‡, Median (IQR), ng/mL P for trend
736 (660–810) 937 (899–970) 1115 (1071–1169) 1332 (1277–1389) 1711 (1567–2011)
No. 132 135 135 132 134
Model 1
Odds ratio (95 % CI) 1.00 1.58 (0.88-2.82) 1.68 (0.94-2.97) 1.59 (0.89-2.83) 2.18 (1.24-3.84)
P value Reference 0.13 0.08 0.12 0.0066 0.011
Model 2
Odds ratio (95 % CI) 1.00 1.59 (0.89-2.86) 1.61 (0.90-2.87) 1.53 (0.85-2.74) 1.96 (1.09-3.51)
P value Reference 0.12 0.10 0.15 0.024 0.025
Model 3
Odds ratio (95 % CI) 1.00 1.69 (0.93-3.08) 1.62 (0.90-2.92) 1.55 (0.85-2.82) 2.10 (1.17-3.78)
P value Reference 0.12 0.11 0.15 0.024 0.026
Model 4
Odds ratio (95 % CI) 1.00 1.79 (0.95-3.39) 1.65 (0.88-3.07) 1.68 (0.89-3.17) 1.97 (1.14-3.57)
P value Reference 0.07 0.12 0.11 0.015 0.030
‡sVCAM-1: Soluble Vascular Cell Adhesion Molecule-1; CI, confidence interval; IQR, interquartile range.
†Missing values = 12 from 680; Model 1: non adjusted; Model 2: adjusted for Biomarkers ( IL6, C-Reactive Protein); Model 3: additionally adjusted for Socio-demographic
condition (Age, gender, White race, Body Mass Index, Current Smoker, Alcohol use, physical activity); Model 4: additionally adjusted for Health conditions (Diabetes,
Hypertension, Congestive Heart failure, Cognitive status, Any cardiovascular medications, Coronary disease, Previous stroke, any cardiovascular medication and
psychotropic medication)
Table 4 Demographics and clinical characteristics of
participants with MRIs at baseline, No =25
Baseline Characteristics MRI data
Demographics
Age, mean (SD), y 77.6 ± 6.3
Women 17 (68.0)
White Race 23 (92.0)
Educational level, median (IQR), y 16 [14–17]
Medical condition
Comorbidity index, mean (SD) 2.7 ± 1.9
Cardiovascular disease 24 (96.0)
Medication
Any psychotropic medication 3 (12.0)
Any cardiovascular medication 16 (64.0)
Brain imaging
White matter hyperintensities volume, mean (SD), mL 15.84 ± 12.61
White matter hyperintensities % ICC, mean (SD) 1.08 ± 0.86
Biomarkers measures
C-Reactive Protein, Mean (SEM),mg/L 1.6 ± 0.5
Interleukin-6, Mean (SEM),pg/mL 2.7 ± 0.6
Soluble ICAM-1, Mean (SEM), ng/mL 268 ± 19
Soluble VCAM-1, Mean (SEM), ng/mL 1172 ± 96
sVCAM-1: Soluble Vascular Cell Adhesion Molecule-1; sICAM-1: Soluble Inter
Cellular Adhesion Molecule-1. *Missing values = 12 from 680
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symptoms seem to have higher WMHs volumes, but in
our small subsample with MRI data, this association did
not reach statistical significance after adjustment for co-
morbidities index.
This current study had some limitations: first, its
cross-sectional design precludes investigating the tem-
poral relation between CAMs and depressive symptoms.
The second is that our population may be not represen-
tative of all older adults. We could only examine the re-
lationship between sVCAM-1 and WMHs in a small
subsample that was willing and able to undergo MRI
studies, which may be not representative of the general
population. The third is that we did not examine other
mechanisms of depressive symptoms. The link between
depressive symptoms and sVCAM-1 may be attributable,
in part, to a common genetic vulnerability or to patho-
physiologic factors, including increased platelet reactiv-
ity, an underlying inflammatory state, or situational
stresses that may be associated with elevated sVCAM-1
plasma levels [35, 36]. We tried to address this in part,
by controlling for the inflammatory biomarkers CRP and
IL6 in the multivariable analysis and our results suggest
that plasma levels of sVCAM-1 was independently asso-
ciated with depression symptoms.
Conclusion
In summary, our study suggests that elevated plasma
levels of sVCAM-1 may be a biomarker for the presence
of cerebral microvascular disease in community-dwelling
elderly people with symptoms of depression. It may be
important to identify elderly people with high levels of
sVCAM-1 as having a high risk of late life depression,
and to treat their atherosclerotic and cardiovascular dis-
ease rigorously for secondary prevention. Additional
prospective studies are needed to confirm our findings
and determine whether sVCAM-1 can serve as a bio-
marker for cerebrovascular causes of depression.
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